AstraZeneca PLC (STO:AZN)
Sweden · Delayed Price · Currency is SEK | Market Cap | 2.41T |
| Revenue (ttm) | 537.29B |
| Net Income (ttm) | 78.88B |
| Shares Out | n/a |
| EPS (ttm) | 50.48 |
| PE Ratio | 30.58 |
| Forward PE | 16.77 |
| Dividend | 32.77 (2.11%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 78,906 |
| Average Volume | 258,006 |
| Open | 1,560.50 |
| Previous Close | 1,559.50 |
| Day's Range | 1,549.50 - 1,561.50 |
| 52-Week Range | 1,226.00 - 1,645.00 |
| Beta | 0.17 |
| RSI | 49.73 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Megacap earnings to dominate next week as government shutdown continues. 11/3/25
The ongoing government shutdown is set to become the second-longest in U.S. history, creating a major hurdle for equities and commodities despite a trade truce with China and a recent Fed rate cut. 10...
AstraZeneca (AZN) Begins Phase 3 Trial for Enhertu in Lung Cancer Treatment
AstraZeneca (AZN) Begins Phase 3 Trial for Enhertu in Lung Cancer Treatment
FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer
The FTSE 100 Index has been in a strong bull run this year and is now trading at a record high of £9,760. It has jumped by 30% from its lowest point this year.
Inside Celosphere 2025: Why there’s no ‘enterprise AI’ without process intelligence
Presented by Celonis AI adoption is accelerating, but results often lag expectations. And enterprise leaders are under pressure to prove measurable ROI from the AI solutions — especially as the use of...
AstraZeneca (AZN) Reports Positive Phase 3 Trial Results for Gefurulimab
AstraZeneca (AZN) Reports Positive Phase 3 Trial Results for Gefurulimab
FDA Streamlines Biosimilar Development; Impacts AstraZeneca (AZN)
FDA Streamlines Biosimilar Development; Impacts AstraZeneca (AZN)
AstraZeneca Shares Surge 3% on Blockbuster Oncology Data and $2 Billion Buyback Boost
AstraZeneca plc (AZN), the most valuable biotech in Europe, and the FTSE 100, shot its shares way up today after announcing convincing Phase III results of its next-generation lung cancer therapy, Dat...
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Astrazeneca (AZN) closed at $82.61 in the latest trading session, marking a -1.72% move from the prior day.
Noteworthy ETF Inflows: SPDW, SAP, AZN, ROG
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...
AstraZeneca's Koselugo Receives EU Approval for Rare Disease Treatment
AstraZeneca's Koselugo Receives EU Approval for Rare Disease Treatment
AstraZeneca (AZN) Upgraded by Jefferies to 'Buy' | AZN Stock News
AstraZeneca (AZN) Upgraded by Jefferies to 'Buy' | AZN Stock News
AstraZeneca found in breach of industry code over Symbicort marketing, industry body says
AstraZeneca breached the UK pharmaceutical industry's code of practice by using a claim that misleadingly implied its Symbicort asthma drug was suitable for all newly diagnosed patients aged 12 years ...
Peering Into AstraZeneca PLC's Recent Short Interest
AstraZeneca PLC's (NYSE: AZN) short interest as a percent of float has fallen 28.0% since its last report. According to exchange reported data, there are now 5.46 million shares sold short , which is...
Novavax (NVAX) Sells Facility to AstraZeneca for $60M in Strategic Deal
Novavax (NVAX) Sells Facility to AstraZeneca for $60M in Strategic Deal
AstraZeneca's Tezspire Receives EU Approval for Severe Rhinosinusitis
AstraZeneca's Tezspire Receives EU Approval for Severe Rhinosinusitis
Novavax to assign Gaithersburg, Md. facility to AstraZeneca for $60B
AstraZeneca Bolsters Oncology with £1.2 Billion Fusion Buyout Amid UK Growth
As part of its move to strengthen its oncology leadership, AstraZeneca has declared the purchase of Fusion Pharmaceuticals at PS1.2 billion, which focuses on novel radioconjugate therapies, as demand ...
AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps
(RTTNews) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for adult patients with s...
AstraZeneca PLC (AZN) Presents at ESMO Congress 2025 - Slideshow
2025-10-21. The following slide deck was published by AstraZeneca PLC in conjunction with this event.
The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies
Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.
Trump’s pharma strategy ‘holds Europe hostage’, Finnish MEP warns
Trump’s deals with Pfizer, AstraZeneca, and Merck expose risk to EU
Top Research Reports for AstraZeneca, RTX & Applied Materials
AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.
AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure
AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure
AstraZeneca hails major breakthroughs with breast-cancer drugs
An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 billion worth of company sales in five years’ time.
AstraZeneca: CHMP Recommends Saphnelo For Approval
(RTTNews) - AstraZeneca (AZN) said its Saphnelo or anifrolumab has been recommended for approval in the European Union as a self-administered once-weekly pre-filled pen for adult patients with systemi...